Who is sponsoring NCT05673668?

NCT05673668 is sponsored by Zhongda Hospital.

What drugs are being tested in NCT05673668?

Interventions in NCT05673668: Endovascular Denervation System (Netrod).

What condition does NCT05673668 study?

NCT05673668 studies Type 2 Diabetes Mellitus (T2DM).

Is NCT05673668 still recruiting?

NCT05673668 is currently status unknown. Last updated 21 July 2023.

Last reviewed 2023-07-21 · How we verify

NCT05673668

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endovascular Denervation (EDN) for the Treatment of Type 2 Diabetes Mellitus

Status unknown NA Last updated 21 July 2023

What this trial tests

NA trial testing Endovascular Denervation System (Netrod) in Type 2 Diabetes Mellitus (T2DM) in 30 participants. Status unknown.

Timeline

27 December 2022

Primary endpoint
30 October 2023

30 April 2024

Quick facts

Lead sponsor	Zhongda Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	27 December 2022
Primary completion	30 October 2023
Estimated completion	30 April 2024
Sites	1 location across China

Drugs / interventions tested

Endovascular Denervation System (Netrod)

Conditions studied

Type 2 Diabetes Mellitus (T2DM) — all drugs for Type 2 Diabetes Mellitus (T2DM) →

Sponsor

Zhongda Hospital

Who can join

Adults 18 to 75, any sex, with Type 2 Diabetes Mellitus (T2DM). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-center, single-arm, self-controlled study to evaluate the effects of endovascular denervation (EDN) on insulin secretory function and insulin sensitivity in the treatment of type 2 diabetes mellitus (T2DM) .

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Interventional metabology: A review of bariatric arterial embolization and endovascular denervation for treating metabolic disorders.
Wang Z, Zhu DQ, Zhu XY, Liu DC, et al · · 2023 · cited 3× · PMID 37438984 · DOI 10.1111/1753-0407.13437
Catheter-based endovascular celiac and hepatic denervation for type 2 diabetes: a multicenter, open-label, single-arm study.
Wang Z, Pan T, Lv W, Tang J, et al · · 2025 · PMID 41233363 · DOI 10.1038/s41392-025-02459-6

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Mellitus (T2DM)

Currently open trials in the same condition.

NCT07533539 — Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration · Phase 1 · recruiting
NCT07366775 — A Telenursing Program to Support Diabetes Self-Management · NA · active not recruiting
NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
NCT07465224 — A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus · Phase 2 · recruiting
NCT07442006 — Glycemic Variability of Combination Therapies in T2DM · Phase 4 · recruiting

Other Zhongda Hospital trials

Trials by the same sponsor.

NCT07516704 — Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoa · EARLY_PHASE1 · not yet recruiting
NCT07504731 — Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability · recruiting
NCT07351669 — A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepato · recruiting
NCT07311915 — Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in Hi · NA · not yet recruiting
NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05673668 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhongda Hospital
Last refreshed: 21 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05673668.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing